Ryma Benayed
Memorial Sloan Kettering Cancer Center(US)AstraZeneca (United States)(US)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Sarcoma Diagnosis and Treatment, RNA modifications and cancer, Cholangiocarcinoma and Gallbladder Cancer Studies
Most-Cited Works
- → Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients(2017)3,455 cited
- → Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children(2018)2,654 cited
- → Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)(2015)2,113 cited
- → Cancer therapy shapes the fitness landscape of clonal hematopoiesis(2020)711 cited
- → Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies(2017)653 cited
- → NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls(2019)522 cited
- → Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing(2017)511 cited
- → High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden(2019)489 cited
- → Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions(2017)467 cited
- → A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors(2017)425 cited